The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy

References

• Papamichael K, Archavlis E, Lariou C, Mantzaris GJ. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn’s disease: a prospective, two-year, single center, pilot study. J Crohn’s Colitis 2012;6:924–31.
   Google Scholar
• Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2014;14:75–101.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 2012;107:1409–22.
   PubMed Web of Science ®Google Scholar
• Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008;57:549–58.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D’Haens G, et al. European Crohn’s and Colitis Organisation (ECCO). European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47–91.
   PubMed Web of Science ®Google Scholar
• Papay P, Eser A, Winkler S, Frantal S, Primas C, Miehsler W, et al. Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:84–90.
   PubMed Web of Science ®Google Scholar
• Papay P, Eser A, Winkler S, Frantal S, Primas C, Miehsler W, et al. Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases. Eur J Clin Invest 2011;41:1071–6.
   PubMed Web of Science ®Google Scholar
• Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309–13.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Flogerzi B, Fallegger S, Schaffer T, Mueller S, Nicod L, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008;103:2799–806.
   PubMed Web of Science ®Google Scholar
• Wong SH, Ip M, Tang W, Lin Z, Kee C, Hung E, et al. Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients. Inflamm Bowel Dis 2014;20:2067–72.
   PubMed Web of Science ®Google Scholar
• Ramos JM, Masiá M, Rodríguez JC, López C, Padilla S, Robledano C, et al. Negative effect of immunosuppressive therapy in the performance of the QuantiFERON gold in-tube test in patients with immune-mediated inflammatory diseases. Clin Exp Med 2013;13:177–86.
   PubMed Web of Science ®Google Scholar
• Shahidi N, Fu YT, Qian H, Bressler B. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2012;18:2034–42.
   PubMed Web of Science ®Google Scholar
• Helwig U, Müller M, Hedderich J, Schreiber S. Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients. J Crohns Colitis 2012;6:419–24.
   PubMed Web of Science ®Google Scholar
• Qumseya BJ, Ananthakrishnan AN, Skaros S, Bonner M, Issa M, Zadvornova Y, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis 2011;17:77–83.
   PubMed Web of Science ®Google Scholar
• Bélard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011;17:2340–9.
   PubMed Web of Science ®Google Scholar
• Hradsky O, Ohem J, Zarubova K, Mitrova K, Durilova M, Kotalova R, et al. Disease activity is an important factor for indeterminate interferon-γ release assay results in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014;58:320–4.
   PubMed Web of Science ®Google Scholar
• Andrisani G, Armuzzi A, Papa A, Marzo M, Felice C, Pugliese D, et al. Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. J Gastrointestin Liver Dis 2013;22:21–5.
   PubMed Web of Science ®Google Scholar
• Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360–1.
   PubMed Web of Science ®Google Scholar
• Lennard L. TPMT in the treatment of Crohn’s disease with azathioprine. Gut 2002;51:143–6.
   PubMed Web of Science ®Google Scholar
• Schaible UE, Kaufmann SH. Malnutrition and infection: complex mechanisms and global impacts. PLoS Med 2007;4:e115.
   PubMed Web of Science ®Google Scholar
• Arias-Guillén M, Riestra S, de Francisco R, Palacios JJ, Belda J, Escalante P, et al. T-cell profiling and the immunodiagnosis of latent tuberculosis infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2014;20:329–38.
   PubMed Web of Science ®Google Scholar
• Swaminath A, Bhadelia N, Wang YC. Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2444–9.
   PubMed Web of Science ®Google Scholar
• Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002;347:1860–6.
   PubMed Web of Science ®Google Scholar
• Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC). Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005;54:49–55.
   PubMedGoogle Scholar
• Papaventsis D, Nikolaou S, Karabela S, Ioannidis P, Konstantinidou E, Marinou I, et al. Tuberculosis in Greece: bacteriologically confirmed cases and anti-tuberculosis drug resistance, 1995-2009. Euro Surveill 2010;15:19614.
   PubMedGoogle Scholar
• Mariette X, Baron G, Tubach F, Lioté F, Combe B, Miceli-Richard C, et al. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 2012;71:1783–90.
   PubMed Web of Science ®Google Scholar